Interim data from an ongoing global phase II trial (CITYSCAPE, NCT03563716) demonstrated the improved efficacy of an anti-TIGIT antibody tiragolumab in combination with anti-PD-L1 antibody atezolizumab compared to atezolizumab alone in PD-L1-positive metastatic NSCLC patients in terms of overall response and progression free survival (105). Here, CD274 is linked to non-small cell lung carcinoma.